【摘 要】
：
Objective:Programmed death-1 (PD-1) receptor-ligand interaction inhibits T cell activation against tumor cells.Pembro is a potent and highly selective humanized monoclonal antibody against PD-1 design
【机 构】
：
Memorial Sloan Kettering Cancer Center, New York, NY, USA
【出 处】
：
第十七届全国临床肿瘤学大会暨2014年CSCO学术年会
论文部分内容阅读
Objective:Programmed death-1 (PD-1) receptor-ligand interaction inhibits T cell activation against tumor cells.Pembro is a potent and highly selective humanized monoclonal antibody against PD-1 designed to directly block its interaction with its ligands, PD-L1 and PD-L2, thus removing the inhibition of T cell activation against cancer.Pembro led to prolonged anti-tumor activity in previously treated NSCLC patients.
其他文献
目的:目前尚无低剂量131I用于治疗低刺激性Tg、不伴有远处转移的高危分化型甲状腺癌的相关研究,本研究旨在探讨低剂量131I在这部分人群中的清甲效果.方法:纳入本回顾性研究的标准为:1)年龄＞18岁;2)分化型甲状腺癌全切术后;3)T4分期(术中肉眼可见甲外侵犯),任何N分期;4)清甲治疗前刺激性Tg≤5ng/ml;5)无远处转移的证据;6)TgAb≤46IU/ml.这部分患者在TSH刺激状态下(
Objective: AZD9291 is an oral, potent, irreversible EGFR-TKI, selective for sensitizing (EGFRm+) and T790M resistance mutations, currently under investigation in an ongoing Phase Ⅰ study of pts with E
Objective: Dacomitinib (D) is an irreversible pan-HER kinase inhibitor.The ARCHER 1009 global phase Ⅲ study compared D and erlotinib (E) as treatment for locally advanced/metastatic non-small cell lun
Objective: To explore the clinical value and biological characteristics of circulating tumor cells (CTCs) in pulmonary vein (CTCs-pv) from patients with surgically resected non-small cell lung cancer
Objective:This Phase Ⅰ study evaluated the safety, tolerability, and clinical activity ofpembro, a selective anti-PD-1 antibody that blocks the interaction between programmed death-1 (PD-1) on T-cells
Objective: We conducted a retrospective study to evaluate the role of prophylactic cranial irradiation (PCI) on patients with surgically resected small cell lung cancer(SCLC).Method: The records of co
Objective: A recent phase 3 study (PARAMOUNT) demonstrated that continuation maintenance therapy of pemetrexed is a new treatment paradigm for advanced nonsquamous NSCLC.The majority of patients enrol
Objeetive: NSCLC are particularly aggressive tumors, with high invasive properties and metastatic potential.About 40％ stage Ⅰ and 60％ stage Ⅱ NSCLC patients are dying of distant metastases within 5 ye
Objective:To identify the feasibility of pleural effusion detection of epidermal growth factor receptor (EGFR) mutations, echinoderm microtubule-associated protein like 4 (EML4)-anaplastic lymphoma ki
背景:厄洛替尼已获FDA批准用于表皮生长因子受体突变(EGFR MT)的非小细胞肺癌(NSCLC)一线治疗,中位无进展生存期(PFS)为10.4个月.Nivolumab是全人源化IgG4程序性死亡1(PD-1)免疫检查点抑制剂抗体,作为单药治疗晚期NSCLC患者显示了出令人鼓舞的安全性与生存获益.临床前数据支持EGFR路径活化PD-L1表达与免疫逃避在EGFR驱动的肺肿瘤中的作用.本摘要将报告评估